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Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in
children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and
those with cardiopulmonary illness, including congenital heart disease (CHD) and bronchopulmonary dysplasia
(BPD). No vaccine is currently approved for the prevention of RSV infection. It is recommended that children at high
risk be prophylactically administered palivizumab, a monoclonal antibody that has been shown in a number of
clinical studies to reduce hospitalization rates due to serious RSV infection. The objective of the current study was
to determine the safety and effectiveness of palivizumab in preventing serious RSV disease in high-risk children in
the Russian Federation. Children at high risk of serious RSV disease (ie, born at ≤35 wk gestational age and ≤6 mo
of age, and/or aged ≤24 mo with BPD or hemodynamically significant CHD) were enrolled. Subjects were to
receive 3 to 5 monthly injections of palivizumab 15 mg/kg (depending on the month of the initial injection) over
the RSV season. The primary endpoint was RSV-related hospitalizations. Adverse events (AEs) were reported through
100 days following the final injection.
Results: One hundred subjects received ≥1 injection of palivizumab; 94 completed their dosing schedule. There
were no RSV hospitalizations or deaths. Six of 7 subjects hospitalized for respiratory/cardiac conditions had an RSV
test, which was negative in all cases. Three non-serious AEs (acute intermittent rhinitis and rhinitis, 1 subject; atopic
dermatitis, 1 subject) were considered possibly related to palivizumab. All other AEs were mild or moderate and
considered not related/probably not related to palivizumab.
Conclusion: Palivizumab was generally well tolerated and effectively prevented serious RSV infection in a mixed
population of high-risk children in the Russian Federation.
Trial registration: ClinicalTrials.gov: NCT01006629
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Respiratory syncytial virus (RSV) is a leading cause of
lower respiratory tract infections (LRTIs) in children
globally [1]. In 2005, an estimated 33.8 million cases of
RSV-associated LRTIs occurred worldwide in children
aged <5 years, with at least 3.4 million resulting in
hospitalization and 66,000–199,000 resulting in death
[1]. RSV infection is prevalent in the Russian Federation.
In a sample of children aged ≤2 years who were hospita-
lized for LRTI during the RSV season, 38% tested posi-
tive for RSV [2]. The prevalence of RSV varied by
geographic region and was highest in Moscow (41.7%).
Activity peaked in April 2009, when RSV was detected
in 62% of children hospitalized for LRTI [2].
Children at high risk for serious RSV disease include
preterm infants and those with cardiopulmonary illness,
including congenital heart disease (CHD) and broncho-
pulmonary dysplasia (BPD). The virus infects airway epi-
thelia and manifests as airway obstruction and increased
airway resistance [3,4]. Once infection is established,
treatment options are limited. Supportive care is the
main treatment strategy for serious LRTIs, as there is
limited evidence of clinical benefit for the only US Food
and Drug Administration− approved antiviral medica-
tion for RSV (ribavirin) [5,6]. Further, RSV induces an
atypical host immune response that fails to generate
robust immunologic memory, leaving patients suscep-
tible to reinfection [3]. Because of the lack of an effective
vaccine [7] and the presence of comorbidities, RSV
prophylaxis by passive immunization is the primary
intervention that can be administered to high-risk chil-
dren to help prevent serious RSV disease.
Palivizumab (MedImmune, LLC, Gaithersburg, MD,
and Abbott, Abbott Park, IL) is a humanized IgG1
monoclonal antibody specific for the F-glycoprotein on
the RSV surface [2,8]. It has neutralizing activity in vitro
and in vivo, [8] and large clinical trials have demon-
strated its efficacy and safety. A large (N = 1502), multi-
center, randomized phase 3 trial conducted in the
United States, Canada, and the United Kingdom showed
that palivizumab prophylaxis reduced RSV-associated
hospitalizations in preterm infants and children aged
≤24 months with BPD by 55% compared with placebo
(4.8% vs 10.6%, respectively; P= 0.00004) [9]. Similarly,
in an international study of children aged ≤24 months
with hemodynamically significant congenital heart
disease (HSCHD; N= 1287), palivizumab prophylaxis
resulted in a 45% reduction in RSV hospitalizations
compared with placebo (5.3% vs 9.7%, respectively;
P= 0.003) [10].
Although palivizumab is approved in more than 60
countries worldwide and has been approved for use in
the United States and Europe for more than a decade, it
only recently (February 2010) received approval in theRussian Federation [2]. This study was initiated before
Russian Federation approval and describes the safety and
effectiveness of palivizumab in the prevention of serious
RSV infection in high-risk children in the Russian
Federation during the 2009–2010 RSV season.
Methods
Study design
This was a multicenter, prospective, open-label, non-
comparative clinical study conducted at 19 sites in 6 geo-
graphically diverse cities within the Russian Federation. Eli-
gible participants were children at high risk of serious RSV
disease, defined as those born at ≤35 weeks gestational age
and ≤6 months of age at enrollment, aged ≤24 months
with a clinical diagnosis of BPD (defined as oxygen require-
ment at a corrected gestational age of 36 wk) requiring
intervention or management (ie, oxygen, diuretics, bronch-
odilators, or corticosteroids) at any time within 6 months
before enrollment, and/or aged ≤24 months with HSCHD
(cyanotic or acyanotic) either not operated on or only par-
tially corrected. Children with acyanotic cardiac lesions
were required to have pulmonary hypertension (≥40 mmHg
measured pressure in the pulmonary artery) or the need
for daily medication to manage CHD. Exclusion criteria
included hospitalization or mechanical ventilation at the
time of enrollment, life expectancy <6 months, active re-
spiratory illness or other infection, known renal or hepatic
impairment, history of seizures (except neonatal seizures),
unstable neurologic disorder, or prior receipt of RSV
prophylaxis. A total of 103 subjects were screened; the par-
ents/guardians of 3 subjects refused to sign the informed
consent form and these 3 subjects were excluded from the
study.
Subjects were to receive palivizumab 15 mg/kg by intra-
muscular injection every 30± 5 days (between 25 and 30 d
for the second dose) for a total of 3 to 5 doses over the
RSV season, depending on the month of the initial injec-
tion. Subjects who developed RSV infection were to con-
tinue their dosing schedule, and those undergoing cardiac
surgery with cardiopulmonary bypass were to receive an
additional injection of palivizumab 15 mg/kg following
surgery.
This study was conducted in accordance with the Dec-
laration of Helsinki and complied with Good Clinical
Practice according to International Conference of Har-
monisation guidelines. The study protocol was reviewed
and approved by the Russian Ministry of Health as well
as federal and local site ethics committees. Written
informed consent from at least 1 parent was obtained
for all subjects.
Local site ethics committees that approved this study
included OF State Institution Scientific Center of Chil-
dren’s Health; Children’s Hospital #1 Saint-Petersburg
State Institution of Healthcare; Moscow Scientific
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Scientific Research Institute for Children’s Infections;
Research Institute of Cardiology, Siberian Branch of the
Russian Academy of Medical Sciences; State Institution
of Cardiovascular Surgery; Center for Obstetrics,
Gynecology, and Perinatology; State Educational Institu-
tion of Higher Professional Education, Saint-Petersburg
State Pediatric Medical Academy; Scientific Center of
Children’s Health of the Russian Academy of Medical
Sciences; State Institution of Health; Saint-Petersburg
State Institution of Health Care; Kazan State Medical
University; Higher Professional Education Novosibirsk
Russian State Medical University of Roszdrav; Ivanovo
Scientific and Research Institute of Mother and
Child named after V.N. Gorodcov Rosmedtechnology;
State Educational Establishment of the Highest Voca-
tional Education, Peoples’ Friendship University of
Russia; State Educational Institution of Higher Profes-
sional Education, Novosibirsk Russian State Medical
University of Roszdrav; and Federal Scientific Clinical Cen-
























The primary endpoint was hospitalization due to RSV in-
fection, which included respiratory/cardiac hospitalization
with a positive RSV test, development of RSV infection in
an already hospitalized subject, or death from RSV infec-
tion at any point from the first dose through 30± 5 d after
the final injection of palivizumab. RSV infection was to be
confirmed within 48 hours of hospitalization using an
immunochromatographic test for detection of RSV anti-
gen (QuickStripe™ RSV, SavyonW Diagnostics Limited,
Ashdod, Israel); nasopharyngeal lavage was the preferred
method of specimen collection. Secondary endpoints
(assessed through 30±5 d after the final injection of palivizu-
mab) included the number of RSV-associated hospitalization
days, number of days with increased supplemental oxygen
requirement, intensive care unit (ICU) admissions, number
of days in the ICU, and the number of subjects and days of
mechanical ventilation, each due to RSV infection. Vital
signs, physical examination findings, and medical and social
history data were recorded. Safety and tolerability were
assessed by treatment-emergent adverse events, defined as
events reported from the first dose of palivizumab through
30 days (“+30-day” period) following the final injection, and
a second assessment extending to 100 days (“+100-day”
period) following the final injection, regardless of suspected




Figure 1 Number of subjects meeting criteria for high risk of
serious RSV disease (N = 100). BPD=bronchopulmonary dysplasia;
HSCHD=hemodynamically significant congenital heart disease;
RSV= respiratory syncytial virus; wGA=weeks gestational age.Statistical analyses
Data were summarized using descriptive statistics. All
subjects who received at least 1 dose of palivizumab
were included in the analyses.Results
One hundred subjects were enrolled in the study and
received at least 1 dose of palivizumab; 94 completed their
dosing schedule. One subject discontinued because of an
adverse event (a nonserious case of atopic dermatitis) and
5 subjects discontinued because of parent unwillingness
to continue participation. A total of 70 subjects were pre-
mature and/or had BPD (Figure 1). All subjects were
white and the majority (73%) were aged <12 months
(Table 1). Mean (SD) gestational age was 33.4 (5.1) weeks
and ranged from 24 to 42 weeks, and mean (SD) birth
weight was 2.14 (1.02) kg. Mean (SD) age at enrollment
was 8.2 (6.3) months and ranged from <1 to 24 months.
Concomitant medications were used by 86% of subjects.
The most common were vitamins (47%), drugs for ob-
structive airway disease (38%), systemic antibacterials
(22%), diuretics (21%), and cardiac drugs (19%). House-
hold conditions considered risk factors for serious RSV
disease or RSV hospitalization are shown in Figure 2. A
total of 47% of subjects lived with other young children,
65% lived in a household with only 1 or 2 rooms, and 24%
were exposed to tobacco smoke.
All dosing occurred between November 2009 and early
April 2010, during the RSV season in the Russian Federation
[2]. Most subjects received the last injection in March and
thus had coverage in April during the peak of RSV season
[2]. Mean (SD) total palivizumab administered per subject
throughout the study was 516.5 (192.3) mg. A total of 26%
of subjects received 4 doses of palivizumab; 65% received 5
doses. Of the 15 subjects who underwent cardiac surgery,
13 had cardiopulmonary bypass. Four of these subjects
received an additional dose of palivizumab (2 of these 4 sub-
jects received a total of 6 doses). Among the remaining 9
subjects, 5 did not receive an additional dose of palivizu-
mab because their regularly scheduled dose was adminis-
tered shortly after surgery, and 4 had surgery either after











Mean (SD), mo 8.2 (6.3)
Median (range), mo 6.0 (<1− 24.0)
Mean (SD) birth weight, kg 2.14 (1.02)
Mean (SD) gestational age, wk 33.4 (5.1)
Medical history,%
Pulmonary* 68
Respiratory distress syndrome/BPD 52
Pneumonia 25
Bronchitis/bronchiolitis 15










Congestive heart failure 7
Cardiac arrhythmia 1
Hospitalized at birth in intensive/critical care unit,% 67
Hospitalized after birth, prior to study enrollment,% 64
BPD bronchopulmonary dysplasia; LRTI lower respiratory tract infection; RSV
respiratory syncytial virus.
*Subjects could contribute to more than 1 category.
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prophylaxis period (n= 3).
Effectiveness
No hospitalizations due to RSV infection occurred dur-
ing the study. Seven subjects were hospitalized during
the study—6 for respiratory and 1 for cardiac condi-
tions. Six of the 7 hospitalized subjects were tested for
RSV antigen; all were negative and none were tested by
viral culture or PCR-based assay to detect RSV nucleic
acids. An RSV test was not performed for 1 subjecthospitalized for respiratory reasons; this hospitalization
was reported to the investigator several weeks later.
The lack of any RSV hospitalizations precluded analysis
of secondary endpoints.
Safety
A total of 80 and 84 adverse events were reported by 41
and 44 subjects in the +30-day and +100-day time peri-
ods, respectively (Table 2), most of which were consid-
ered not related to palivizumab. Only 3 adverse events
(rhinitis and acute intermittent rhinitis [both occurring
in 1 subject] and atopic dermatitis) were considered pos-
sibly related to palivizumab. The case of atopic derma-
titis (considered mild in severity by the investigator) was
the only adverse event that led to a subject being discon-
tinued from the study. Adverse events were reported as
severe in 3 subjects (arrhythmia, pneumonia, and tonsil-
litis); however, these events were not considered related
to the study drug. Serious adverse events occurred in 10
subjects overall (9 subjects during the +30-day period
and 10 during the +100-day period); none were consid-
ered related to the study drug. No deaths were reported
during the study.
Discussion
In this study, palivizumab was generally well tolerated
and effectively prevented serious RSV infection in a
mixed population of high-risk children in the Russian
Federation. There were no hospitalizations due to RSV
infection, few treatment-related adverse events, no ser-
ious treatment-related adverse events, and no deaths
reported in this study.
Placebo-controlled clinical trials, [9,10] observational
studies, [11,12] and postmarketing data [13-15] from
North America and Europe previously established the ef-
ficacy of palivizumab prophylaxis. Multiple studies com-
paring the rates of RSV hospitalization before and after
the introduction of palivizumab have demonstrated that
RSV hospitalizations were reduced after prophylaxis by
66%–92% in various populations of high-risk children
[11,12,15]. One study reported no difference in the rate
of RSV hospitalization after the introduction of palivizu-
mab, but the baseline incidence of RSV hospitalization
in this population of high-risk children was lower before
prophylaxis (3.8%)[16] compared with the baseline RSV
incidence for high-risk populations reported in other
studies (~13%–44%) [11,12,15]. Postmarketing registry
studies conducted in the United States and Canada have
also reported low rates of RSV hospitalizations (0.3%–
2.9%) in high-risk children who received palivizumab
prophylaxis [13,14]. A recent meta-analysis reported that
the relative risk of hospitalization for children who had
received palivizumab versus placebo was 0.5 (95% CI,































































Other children in home
aged ≤13 years*
1 2 3 >3
Figure 2 (A) Household conditions and (B) exposure to tobacco smoke (N = 100). *n = 47.
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was 20 (95% CI, 9–30) [17]. Consistent with the previ-
ously demonstrated effectiveness of palivizumab prophy-
laxis, there were no hospitalizations for RSV among
high-risk children in the Russian Federation in the
current study.
Initial clinical trials of palivizumab reported low rates
of potentially treatment-related adverse events that were
similar to those reported for placebo (7%–11% for both
groups) [9,10]. Postmarketing surveillance programs
have also shown low rates of adverse events in larger
populations. In these studies, serious adverse events
were reported in ≤1% of patients [13,14]. This is consist-
ent with the favorable safety profile observed in the
current study. There were only 3 adverse events consid-
ered possibly related to palivizumab; only 1 of these ad-
verse events (a mild case of atopic dermatitis) led to
subject discontinuation from the study.
Limitations of this study include the small sample size
and the lack of a placebo control group. Two previous
international clinical trials, each enrolling more than
1200 subjects with similar baseline health conditions as
in the present study, have shown that the incidence of
RSV-associated hospitalizations in subjects who received
palivizumab and those who received placebo was ~5%Table 2 Most common adverse events* (≥4% of subjects) by
Adverse event,% of subjects† Total Mil




Upper respiratory tract infection 9 6
Respiratory, thoracic, and mediastinal disorders} 4 3
Dermatitis 4 4
*Adverse events were defined as treatment-emergent events, occurring after study
†Subjects could have experienced more than 1 adverse event.
{Includes anal stenosis, enteritis, and teething.
}Includes bronchopulmonary dysplasia, rhinorrhea, and tonsillar hypertrophy.
||One case each of pneumonia and tonsillitis.
}Possibly related to study drug.and ~10%, respectively [9,10]. Based on these data, it
was expected that several RSV hospitalizations would be
observed in the present study with 100 children enrolled.
Because the study was conducted during only one RSV
season, it is possible that the hospitalization rate may
have been lower due to a comparatively mild RSV sea-
son. Six of the 7 hospitalized subjects were tested for
RSV antigen; all were negative and none were tested by
viral culture. The absence of antigen alone does not
completely discount the possibility of infection. None-
theless, the lack of serious RSV infections in this study
further supports the overall effectiveness of palivizumab.
Formal demonstration of efficacy would have required a
control group; however, the results of this study are con-
sistent with the known efficacy and safety profile of
palivizumab.
As noted, pivotal clinical trials and postmarketing
studies of palivizumab have been conducted in devel-
oped, western countries to date. An important consider-
ation in assessing the effectiveness of therapy with
palivizumab is the conditions in which high-risk children
are living. Environmental and socioeconomic factors, in-
cluding crowded living conditions, other young children
in the home, and exposure to tobacco smoke, may be
important risk factors for RSV infection, severe RSVseverity and relationship to study drug (N=100)








drug initiation and within 100 days after the last dose of study drug.
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present study population, nearly half of the subjects lived
with other young children, the majority lived in a house-
hold with only 1 or 2 rooms, and 24% were exposed to
tobacco smoke. Because these factors are often more
prevalent in developing countries, [22,23] it was import-
ant to conduct this study in a population living under
non-western conditions that are representative of much
of the developing world.
Premature birth, BPD, and CHD are additional known
risk factors for serious RSV disease [19]. The number of
children surviving with these conditions in the Russian
Federation is expected to increase in 2012, when the
country will adopt the World Health Organization defin-
ition of live birth. The expanded live birth criteria will
include infants born with any sign of life, compared with
the current Soviet-era definition requiring respirations,
birth weight ≥1000 g, and ≥28 weeks gestational age
(unless surviving 7 days) [24,25]. It is anticipated that
this change and success in the intensive care of preterm
infants with extremely low birth weight in the Russian
Federation will increase the number of surviving infants
and thus the number considered at high risk for serious
RSV disease.
Conclusions
The current study of palivizumab in a mixed population
of children at high risk of serious RSV infection in the
Russian Federation is consistent with previous reports of
palivizumab safety and efficacy from large, placebo-
controlled trials conducted in other countries. These
data highlight the importance of access to palivizumab
immunoprophylaxis in the Russian Federation.
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